Clinical trial
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
NCT03704688 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- October 9, 2018
- Completion date
- February 4, 2022
- Enrollment
- 12 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
kras gene mutation, non small cell lung cancer